Singapore’s Priority-Review Scheme Goes Live
Executive Summary
Only marketing applications submitted on or after Aug. 22 will be considered for Singapore’s new priority-review scheme for medical devices.
You may also be interested in...
Asia Reg Roundup: Vietnam's Medtech Filers Under More Deadline Pressures
Stakeholders aired concern in Vietnam this summer about the amount of time available for companies to meet the new national device regulatory system's July 1 deadline for class A, lowest-risk, medical device applications. There are now worries over whether the next deadline, December 31, will be met for the higher-risk category devices, according to local experts Jack Wong and May Ng in this regional update that also includes updates from Malaysia, Bangladesh and Hong Kong.
Medtech Associations Regulatory Networking, July 2017 – Singapore, the Philippines, Myanmar
The first Medtech Associations Regulatory Networking discussion, hosted by Medtech Insight and sponsored by the ARQon consultancy (Singapore) and the Asia Regulatory Professionals Association (ARPA), was held in mid-July. Updates were received from senior regulatory figures in three Asian medtech markets where regulation is evolving fast – Singapore, the Philippines and Myanmar.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.